Physician profile
Vera Goode
NPI 1023081965
$8,833.93
in general payments reported to CMS, 2019-2025
34 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $544 · 2021: $495 · 2022: $3,988 · 2023: $1,336 · 2024: $1,016 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,335 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,334.62 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,078.48 | 2021-2025 | |
| Novo Nordisk INC | $1,094.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $834.26 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $423.38 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $344.62 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $344.56 | 2022-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $326.72 | 2019-2025 | |
| Astellas Pharma US INC | $162.46 | 2020-2024 | Veozah, Myrbetriq |
| Mylan Specialty L.P. | $110.05 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.15 | 2019-2022 | |
| Abbott Laboratories | $99.42 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $79.59 | 2019-2021 | |
| Amarin Pharma, INC. | $73.32 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $60.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $60.48 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $55.38 | 2023 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.93 | 2019-2020 | |
| Gilead Sciences, INC. | $51.81 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $48.64 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $48.34 | 2025 | Auvelity |
| Exact Sciences Corporation | $44.86 | 2024-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $44.85 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.92 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.09 | 2024-2025 | Caplyta |
| Amgen INC. | $32.90 | 2019 | |
| Eisai INC. | $26.12 | 2024 | |
| Almatica Pharma LLC | $24.13 | 2022 | |
| Phadia US INC. | $23.76 | 2025 | Immunocap |
| Corcept Therapeutics | $21.18 | 2025 | Korlym |
| Ultragenyx Pharmaceutical INC. | $18.70 | 2021 | |
| Lundbeck LLC | $18.54 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $18.29 | 2025 | Trintellix |
| Nestle Healthcare Nutrition INC. | $15.76 | 2022 | |
| Currax Pharmaceuticals LLC | $14.40 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Goode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.